Lipid Biomarkers and Cardiovascular Risk Which Path to Take at the Fork in the Road?∗ by Nicholls, Stephen J. & Kritharides, Leonard
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 5 , N O . 1 3 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 2 . 0 1 5EDITORIAL COMMENTLipid Biomarkers and Cardiovascular Risk
Which Path to Take at the Fork in the Road?*Stephen J. Nicholls, MBBS, PHD,y Leonard Kritharides, MBBS, PHDzSEE PAGE 1286S ince Anitschkow’s seminal observation ofaortic atherosclerosis formation in response tofeeding a high-cholesterol diet, abundant evi-
dence has afﬁrmed the pivotal role of lipids in cardio-
vascular disease (CVD) (1). Subsequent randomized
controlled trials have unequivocally demonstrated
that lowering atherogenic cholesterol levels reduces
cardiovascular (CV) event rates in both the primary
and secondary prevention setting (2). The demonstra-
tion of greater beneﬁt in patients who achieve more
intensive lipid lowering has stimulated treatment
guidelines throughout the world to promote more
aggressive intervention in high-risk individuals (3).
The ﬁnding that many patients continue to experi-
ence clinical events, despite using statin therapy,
suggests that there is an ongoing need to develop
novel strategies to achieve more effective risk reduc-
tion in our patients.
In parallel, increasingly, insights from pre-clinical
and pathology studies have highlighted the impor-
tant role of oxidation and inﬂammation in the path-
ogenesis of atherosclerotic disease. In addition to
their role in endothelial activation, the earliest
abnormality of the artery wall, oxidation and in-
ﬂammation are implicated in the formation of foam
cells, the cellular hallmark of atherosclerotic plaque
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dant properties have so far failed to reduce CV risk in
large outcome trials, there continues to be immense
interest in approaches that target the oxidation
component of CVD.
Oxidized phospholipids (oxPL) impart a direct in-
ﬂuence on inﬂammatory pathways within the artery
wall and have received considerable attention as
targets for biomarker and therapeutic development.
The murine monoclonal antibody E06 binds to the
phosphocholine head group of oxidized, but not
nonoxidized, phospholipids. These antibodies have
been employed to demonstrate oxPL species within
atheroma samples (4) and to develop blood-based
assays that have been shown to predict the risk of
CV events in community-based cohorts (5). Still, to
date, this assay’s predictive capacity has not been
evaluated in patients with established coronary
artery disease (CAD).In this issue of the Journal, Byun et al. (6) have
evaluated this assay in a random sample of patients
who participated in the TNT (Treating to New Tar-
gets) study, in which low- and high-dose atorvastatin
were directly compared in the secondary prevention
setting. Following an 8-week run-in treatment period
with atorvastatin 10-mg daily, baseline levels of
oxPL-apolipoprotein B (apoB) were higher in patients
who subsequently experienced a CV event. This per-
sisted on multivariable analysis, controlling for other
clinical and biochemical parameters. Interestingly,
this relationship was only observed in patients
treated with atorvastatin 10-mg daily, not those
treated with the higher 80 mg dose. Further analysis
failed to demonstrate an association between follow-
up oxPL-apoB levels or their serial change with car-
diovascular events.
These are intriguing ﬁndings. They extend the
published data demonstrating an association between
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1297oxPL assays and CV risk in patients with established
CVD. The ﬁnding that oxPL is predominantly carried
by the enigmatic lipoprotein(a) and that there is a
direct relationship between their levels and CV
events may provide further mechanistic rationale for
the role of lipoprotein(a) in the pathogenesis of CVD.
However, there remain many unanswered ques-
tions. All patients in this substudy had undergone
8 weeks of treatment with low-dose atorvastatin
before baseline oxPL-apoB levels were measured.
Thus, the relationship between oxPL-apoB levels and
CV risk in statin-naïve CAD patients remains to be
tested. The ﬁnding that the relationship is only
observed in patients treated with the lower atorvas-
tatin dose is notable. It is unknown whether this is
related to greater lowering of atherogenic cholesterol
or potentially more pleiotropic effects on oxidative
and inﬂammatory pathways with high-intensity
atorvastatin. The lack of association between serial
measures of oxPL-apoB and CV events requires
further investigation. The ﬁnding that oxPL-apoB
levels rise with statin therapy and plaque regression
has been postulated to reﬂect the removal of oxPL
from the artery wall to the circulation and may in-
ﬂuence interpretation of serial changes and CV risk.
Also, the lack of signiﬁcant improvement of
receiver-operating curve analysis in this study, in
contrast to prior reports in primary prevention, re-
quires further consideration. Whether this reﬂects
limited statistical power or the inﬂuence of other
factors in patients with established CAD is unknown.
Finally, it is acknowledged that the oxPL-apoB assay
identiﬁes some, but not all, oxPL populations.
Whether the other unmeasured oxPL species are more
or less important in terms of inﬂuencing CV risk
remains to be established.
The current analysis is but 1 step in the develop-
ment pathway of a novel CV biomarker. Further steps
along that path will require ongoing elucidation of
what is precisely measured by this assay, both instatic and serial studies. Applying this assay to addi-
tional cohorts will be important to provide further
validation of its predictive capacity and its ability to
reclassify cardiovascular risk beyond currently-
employed algorithms. Ultimately, implementation
studies will be required to delineate how to most
optimally use this assay, how it changes manage-
ment, and its cost effectiveness. Accordingly, a
considerable amount of work remains to be done.
In addition, the development of a novel lipid
biomarker must be considered in the landscape of
current approaches to predicting CV risk. Despite the
emergence of new approaches to quantify athero-
genic lipids, including non–high-density lipoprotein
cholesterol, particle-based parameters, and now
measures of oxidized lipid species, we still face
considerable uncertainty as to how to use these fac-
tors that go beyond simply measuring low-density
lipoprotein or total cholesterol. Recent updates
to treatment guidelines for dyslipidemia have
highlighted the need to use more intensive lipid
lowering for the highest-risk patients, yet these
documents often provide little guidance on how to
use these novel lipid biomarkers to reﬁne our risk
stratiﬁcation to identify the individual patients most
likely to derive clinical beneﬁt from intensiﬁcation
of lipid-lowering therapy (3). Such stratiﬁcation is
likely to be of increasing importance as additional
therapies come to clinical practice, and careful, cost-
effective patient selection will be mandatory. More
clinical trials speciﬁcally testing the utility of novel
biomarkers, such as oxPL, to predict baseline and
on-treatment risk in various populations will be
needed.
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